Fate Therapeutics

Fate Therapeutics EBIT Margin

The EBIT Margin (Operating Margin) of Fate Therapeutics (FATE) as of Oct 24, 2026 is -2,222.45 %. In the previous year, EBIT Margin (Operating Margin) was -1,542.63 % — a change of 44.07% (lower).

EBIT Margin

-2,222.45 %

YoY

44.07%

Last updated:

EBIT Margin (Operating Margin) of Fate Therapeutics is 2025 -2,222.45 % . EBIT Margin (Operating Margin) of Fate Therapeutics was 2024 -1,542.63 % . It decreases by 44.07% lower compared to the previous year.

Fate Therapeutics's operating (EBIT) margin stands at -2,222.4%, down from -388.6% several years earlier.

The Fate Therapeutics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-1,415.44 USD
Jan 1, 2019
-943.14 USD
Jan 1, 2020
-407.47 USD
Jan 1, 2021
-388.56 USD
Jan 1, 2022
-320.23 USD
Jan 1, 2023
-299.86 USD
Jan 1, 2024
-1,542.63 USD
Jan 1, 2025
-2,222.45 USD
The Fate Therapeutics EBIT Margin history
YEAREBIT MarginYoY
-2,222.45 %+44.07%
-1,542.63 %+414.45%
-299.86 %-6.36%
-320.23 %-17.58%
-388.56 %-4.64%
-407.47 %-56.80%
-943.14 %-33.37%
-1,415.44 %+37.58%
-1,028.81 %+41.69%
-726.10 %-36.46%
-1,142.82 %+6,178.25%
-18.20 %+258.50%
-5.08 %-55.31%
-11.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fate Therapeutics Stock analysis

What does Fate Therapeutics do? Fate Therapeutics Inc is a biotechnology company specializing in the development of cell therapies. The company was founded in 2007 by four scientists who recognized the need for new therapies and treatment options. Their goal was to find new ways to promote tissue and organ regeneration and repair by harnessing the biological mechanisms within cells. Fate Therapeutics' business model is to develop and market state-of-the-art cell therapies based on human stem cells. These stem cells are typically obtained from patients' bone marrow or adipose tissue and then cultured in specialized cell cultures to prepare them for medical use. Fate Therapeutics currently offers several different products and services, including: - Cell therapies for the treatment of cancer: The company has developed a range of cell therapies aimed at boosting the immune system and mobilizing against cancer cells. These therapies are based on the method of extracting so-called T cells from the patient's blood, growing and modifying them in the lab to enhance their ability to target cancer cells. - Therapies for the treatment of genetic diseases: Fate Therapeutics has also developed cell therapies aimed at treating genetic mutations or defects. These therapies are based on the method of obtaining pluripotent stem cells (iPS cells) from the patient's blood or adipose tissue and then differentiating them into specialized cell types that can be used to repair tissue damage or correct genetic defects. - Services to support research and development: Fate Therapeutics also offers services to assist researchers in developing and testing their own cell therapies. This includes the cell cultures, devices, and assays needed to generate and analyze new cell lines. Fate Therapeutics is divided into several divisions to better manage its various business areas. These divisions include: - Research & Development: This division is responsible for conducting basic research to develop and test new cell therapies. This includes both foundational research and the clinical trials necessary to evaluate the effectiveness and safety of new therapies. - Manufacturing: This division is responsible for the large-scale production and processing of Fate Therapeutics' cell therapies. The company has multiple production facilities in the United States and internationally to ensure swift and efficient manufacturing and delivery of its therapies. - Sales & Marketing: This division is responsible for marketing and selling Fate Therapeutics' cell therapies. The company works closely with doctors, clinics, and medical facilities to ensure that therapies reach the patients who need them. Overall, Fate Therapeutics has become a global leader in the development of cell therapies. The company has made significant progress in recent years in developing new therapies and continues to work on finding innovative solutions to medical challenges. With its competent leadership and top-notch products and services, Fate Therapeutics Inc. is poised for even greater success in the future. Fate Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fate Therapeutics stock

EBIT Margin (Operating Margin) of Fate Therapeutics is -2,222.45 % in 2025.

EBIT Margin (Operating Margin) of Fate Therapeutics changed from -1,542.63 % to -2,222.45 %, representing a 44.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Fate Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Fate Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Fate Therapeutics

All Key Metrics — Fate Therapeutics